Read carefully before use
25 mg tablets
White or almost white biconvex tablets.
Each tablet contains:
Active ingredient: cinnarizine 25 mg.
Excipients: lactose monohydrate, potato starch, povidone, anhydrous colloidal silicon dioxide, and magnesium stearate.
Cinnarizine belongs to calcium antagonists. Cinnarizine improves microcirculation. Cinnarizine suppresses nystagmus (uncontrolled eye movements), and other manifestations of vestibular disorders. Cinnarizine has an antihistamine (anti-allergic) effect.
Symptomatic treatment of vestibular disorders (labyrinthine vertigo, including dizziness, nausea, vomiting, tinnitus, and nystagmus).
Prevention of kinetosis (motion sickness).
Symptomatic therapy for disorders of the peripheral circulation (intermittent claudication syndrome) in adults.
Diseases of the inner ear: 1 tablet 3 times a day (75 mg per day).
Violation of peripheral circulation: 2-3 tablets 3 times a day (150-225 mg per day).
The treatment course duration is determined by a doctor.
Motion sickness prevention: 1 tablet (25 mg) half an hour before travel. Can be repeated once in 6 hours.
Children and adolescents:
Motion sickness prevention: half the adult dose is recommended for children aged 5-12 years.
Elderly people: no data available.
Use in hepatic impairment: no data available.
Use in renal insufficiency: no data available.
Cinnarizine-NAN should be preferably taken after meals.
The maximum recommended daily dose should not exceed 225 mg (9 tablets).
Since the effect of Cinnarizine-NAN on dizziness is dose-dependent, the dose should be increased gradually.
Symptoms such as drowsiness and gastrointestinal disturbances may occur. They are usually transient and can be prevented by gradually reaching the optimal dose.
In rare cases, headache, dry mouth, weight gain, excessive sweating, and allergic reactions may occur. In very rare cases, symptoms of lichen planus and lupus-like symptoms have been reported.
A single case of cholestatic jaundice has been reported in the medical literature.
Rare cases of aggravation or development of extrapyramidal symptoms have been observed mainly in the elderly people during long-term treatment. In such cases, the treatment should be discontinued.
In the event of adverse reactions, including those not listed in this leaflet, one should stop using the medicinal product and consult a doctor.
|Primary System Organ Class (MedDRA 9.1)
|Immune system disorders
|Hypersensitivity (allergic reactions)
|Nervous system disorders
|Liver and bile duct disorders
|Skin and subcutaneous tissue disorders
|Hyperhidrosis (excessive sweating)
|Musculoskeletal and connective tissue disorders
Hypersensitivity to the active substance or to any of the excipients.
Symptoms: vomiting, drowsiness, coma, tremor, arterial hypotension, extrapyramidal symptoms, and convulsions (in children).
Treatment: there is no specific antidote.
Gastric lavage in the first hour after an overdose, administration of activated charcoal, symptomatic and supportive therapy.
The concomitant use of alcohol, use of CNS depressants, or tricyclic antidepressants may increase the sedative effect of any of the listed pharmaceuticals or Cinnarizine-NAN.
Due to an antihistamine effect, cinnarizine can neutralize positive reactions during diagnostic skin tests (treatment should be canceled 4 days before testing).
If taking other medicines at the same time, one should consult a doctor.
Cinnarizine (like other antihistamine medicines) may cause stomach discomfort. Taking the medicinal product after a meal can reduce irritation of the gastric mucosa.
Since cinnarizine can cause drowsiness, it should be used with extreme caution in conjunction with medicinal products that have a depressant effect on the central nervous system.
For patients with Parkinson’s disease, cinnarizine should only be prescribed if the benefit of therapy outweighs the possible risk of aggravating the disease.
It is necessary to prescribe the medicinal product with caution to patients over 65 years of age, to children, and to the patients with extrapyramidal disorders in their family history or within their clinical symptoms.
Cinnarizine should be used with caution in the patients with hepatic or renal insufficiency.
During treatment it is necessary to control blood pressure for the persons prone to hypotension.
Due to the presence of an antihistamine effect, cinnarizine can affect the result in the anti-doping control of athletes (false positive result), as well as neutralize positive reactions during diagnostic skin tests (treatment should be canceled 4 days before testing).
Due to the availability of lactose, the medicinal product should not be administered to patients with galactose intolerance, lactase deficiency, or glucose-galactose malabsorption.
If symptoms persist or worsen while taking the medicine, one should consult a doctor.
Cinnarizine-NAN is not recommended for pregnant women.
There are no data on the excretion of Cinnarizine-NAN into breast milk, so the women taking Cinnarizine-NAN should avoid breastfeeding.
Cinnarizine-NAN is contraindicated for use in children under 5 years old due to lack of sufficient data.
Cinnarizine can cause drowsiness, especially at the beginning of treatment. In the event of such an effect, patients should not drive and use machines.
25 tablets in a blister pack. 1 or 2 blisters and a patient information leaflet in a carton pack.
Protect from light and moisture. Store at temperatures not exceeding 25°C. Keep out of the reach of children.
2 years. Do not use after the expiration date.
State enterprise ACADEMPHARM
220141, 5/3 Kuprevicha Street, Minsk, Belarus,
Phone / Fax +375 17 268-63-64
To report adverse reactions use the electronic application form on the manufacturer’s website: https://academpharm.by/en